We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

EPI-743 in Friedreich's Ataxia Point Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01962363
Recruitment Status : Completed
First Posted : October 14, 2013
Last Update Posted : June 29, 2016
Edison Pharmaceuticals Inc
Friedreich's Ataxia Research Alliance
Information provided by (Responsible Party):
University of South Florida

Brief Summary:
The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations

Condition or disease Intervention/treatment Phase
Friedreich's Ataxia Drug: EPI-743 Phase 2

Detailed Description:
The primary objective of this study is to investigate whether treatment with EPI-743 has a discernible impact on visual function-including visual acuity, visual fields and color vision as well as on any of a number of functional and subject/clinician-rated scales relevant in the treatment of Friedreich's ataxia, and to determine the safety of treatment with EPI-743.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations
Study Start Date : October 2013
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: EPI-743
EPI-743, oral, 400mg three times daily for 3 months
Drug: EPI-743
EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
Other Name: Vincerinone, alpha-tocotrienol quinone

Primary Outcome Measures :
  1. Visual function [ Time Frame: 3 months ]
    Low contrast acuity

  2. Safety parameters [ Time Frame: 3 months ]
    Clinical and laboratory safety parameters

Secondary Outcome Measures :
  1. Visual function [ Time Frame: 3 months ]
    Visual fields as assessed by Humphrey 30-2 exam; High contrast visual acuity

  2. Neurologic function [ Time Frame: 3 months ]
    Friedreich's Ataxia Rating Scale

  3. Physical function [ Time Frame: 3 months ]
    25-foot walk (for subjects capable of completing the test on enrollment);

  4. Health related quality of life [ Time Frame: 3 months ]
    Patient report via rating scale

  5. Activities of Daily Living [ Time Frame: 3 months ]
    Patient report via rating scale

  6. Cardiac indices [ Time Frame: 3 months ]

  7. Upper extremity function [ Time Frame: 3 months ]
    9 hole peg test

  8. Disease biomarkers [ Time Frame: 3 months ]
    Glutathione cycle components

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of genetically confirmed Friedreich's ataxia point mutation.
  2. Visual acuity at baseline more than 15 letters on high contrast EDTRS at four meters.
  3. FARS score of 20 to 90.
  4. Male or female between 18 and 65 years of age.
  5. Agreement to use contraception if within reproductive years
  6. Hormone replacement therapy, if used, must remain stable for the duration of the study.
  7. Willingness and ability to comply with study procedures.
  8. Willingness and ability to arrive at study site metropolitan area day prior to evaluations.
  9. Abstention from use of dietary supplements and non-prescribed medications at least 30 days prior to initiation of treatment and for the duration of the study. This would specifically include idebenone, Coenzyme Q10 and vitamin E.
  10. Abstention from foods or beverages or bars fortified with Coenzyme Q10, vitamin E, super fortified functional foods or beverages at least 30 days prior to initiation of treatment and for the duration of the study.
  11. Abstention from use of other investigative or non-approved drugs within 30 days of enrollment and for the duration of the study.
  12. Subject can swallow multiple size 0 capsules.
  13. Subject has voluntarily signed an IRB approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.

Exclusion Criteria:

  1. Allergy to EPI-743 or sesame oil or nuts.
  2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR > two; PTT > two-times normal).
  3. Liver insufficiency with LFTs greater than three-times upper normal limit at screening.
  4. Renal insufficiency with creatinine > 1.5 at screening.
  5. Fat malabsorption syndromes.
  6. Any other respiratory chain diseases of the mitochondria or inborn errors of metabolism.
  7. Any other ophthalmologic conditions.
  8. Clinically significant cardiomyopathy with ejection fraction < 40 percent at screening.
  9. Clinically significant arrhythmia within past two years requiring treatment.
  10. Surgery planned through the duration of the study, including follow-up.
  11. Pregnancy or breastfeeding.
  12. Anticoagulant therapy within 30 days of enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01962363

Layout table for location information
United States, Florida
University of South Florida
Tampa, Florida, United States, 33612
Sponsors and Collaborators
University of South Florida
Edison Pharmaceuticals Inc
Friedreich's Ataxia Research Alliance
Layout table for investigator information
Principal Investigator: Theresa A Zesiewicz, MD University of South Florida
Layout table for additonal information
Responsible Party: University of South Florida
ClinicalTrials.gov Identifier: NCT01962363    
Other Study ID Numbers: EPI-743 PM
First Posted: October 14, 2013    Key Record Dates
Last Update Posted: June 29, 2016
Last Verified: June 2016
Keywords provided by University of South Florida:
Friedreich's ataxia point mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebellar Ataxia
Friedreich Ataxia
Neurologic Manifestations
Nervous System Diseases
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Tocotrienol, alpha
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs